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Breast cancer remains the most common female cancer worldwide. The major-
ity will arise spontaneously, with almost a third having a heritable component. 
Approximately 5–10% of all breast cancers will have a strong inherited element 
with pathogenic variants in the BRCA1 and BRCA2 amongst the most studied 
breast cancer genes. An overview of breast cancer is provided with references to the 
clinical and pathological features in BRCA1 and BRCA2 related cancers. The roles 
of PARP inhibitors and immunotherapy are discussed. The management of healthy 
individuals harbouring a pathogenic variant in the two genes is reviewed and future 
directions considered.
Keywords: BRCA1, BRCA2, breast cancer, risk reduction, mastectomy,  
pathogenic variant
1. Introduction
Breast cancer remains the most common cancer amongst women in the world 
[1]. In the UK, 25% of all female cancers originate from the breast with estimates 
that 1 in 7–10 will develop this disease during their lifetime [2]. In 2018, there were 
over 2 million new cases of breast cancer worldwide, accounting for almost 12% of 
all cancer [3]. In developed countries, almost 80% of breast cancers occur in post-
menopausal women, predominantly in the Caucasian population.
Breast cancer represents a heterogenous disease process and an understanding 
of the clinical aspects is required prior to appreciating the aspects of breast cancer 
amongst BRCA1/2 pathogenic variant (PV) carriers.
2. Invasive or in-situ (non-invasive cancer)
The vast majority of breast cancers are invasive (up to 90%) presenting via 
a symptomatic pathway. In contrast, in-situ disease tends to be more commonly 
identified via breast screening programmes (e.g., NHSBSP) with advances in 
digital mammography or incidentally. In the USA, in situ disease comprises 
almost 25% of all breast cancers, 80% of which are identified by breast  
screening [4].
In histopathological terms, invasive cancers will have breached the basement 
membrane with metastatic potential compared with the more innocuous in-situ 
disease where the disease process is contained within the basement membrane, with 
theoretically limited or no metastatic potential.
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3. Ductal or lobular origin
The microanatomy of the breast can be considered to comprise of terminal 
ductal lobular unit [5, 6]. Each breast lobule is by a collecting duct terminating in 
the lobule. This serves as the basic functional unit of the breast. Invasive ductal car-
cinoma (also termed no special type carcinoma) represents the most common type 
of breast cancer accounting for almost 80% of cancer. Invasive lobular carcinoma is 
less common accounting for almost 10% of cases.
These two types of breast cancer are biologically different. Invasive lobular cancers 
tend to have a more spreading growth pattern, meaning that they can be more difficult 
to diagnose or size on routine mammograms or clinical examination. In addition, they 
may be resistant to neo-adjuvant chemotherapy. Invasive lobular cancers tend to be 
more hormone-sensitive, HER2 negative and lower grade breast cancer (see below).
4. Grade of breast cancer
This refers to the microscope assessment of the breast cancer and determining 
how the cells look compared with normal breast tissue [6]. This in turn will predict 
the biological activity of the breast cancer, with high-grade tumours considered to 
be faster growing with a more aggressive behaviour.
4.1 Grades in in-situ disease
Low grade—slow growing and more closely resemble normal breast tissue.
Moderate/intermediate grade—more abnormal looking compared with low 
grade, with a more rapid growth pattern.
High grade—cells look quite different to normal breast tissue, grow quicker with 
an increased chance of progressing to an invasive cancer.
4.2 Grades in invasive cancer
There are three different grades of invasive breast cancer based on an assessment 
of tubule formation, nuclear pleomorphism and mitotic count:
Grade 1 (well differentiated).
Grade 2 (moderately differentiated).
Grade 3 (poorly differentiated).
5. Hormone receptor status
Oestrogen receptors (ER) were first identified in 1958 (Elwood, Chicago) but an 
appreciation of the hormonal component of breast cancer predates this to the 1890s 
when George Beatson performed oophorectomy as a treatment for breast cancer in 
women [7]. It still remains a critical biological factor in the modern day manage-
ment of breast cancer.
The oestrogen (ER) and progesterone receptors (PR) relevant to breast cancer 
are intracellular receptors that are activated by the hormone oestrogen (17 beta 
oestrodiol) acting as a DNA-binding transcription factor, in particular stimulation 
of mammary cells.
Approximately 70–80% of breast cancers overexpress ER [8]. These hormone 
sensitive breast cancers may be treated with anti-hormone therapy by either selec-
tive oestrogen receptor modulators (e.g., Tamoxifen) or aromatase inhibitors.
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6. HER2 receptor status
The HER2 receptor (human epidermal growth factor receptor) is a trans-
membrane tyrosine kinase that is overexpressed in 15–20% of breast cancers [9]. 
Amplification of this oncogene is considered a marker of aggressiveness and is an 
important biomarker for targeted therapy. Drugs targeting the HER2 receptor (e.g., 
Trastuzumab, Pertuzumab) have significantly altered the clinical outcomes of 
otherwise poor prognosis HER2 positive breast cancers.
7. Molecular subtypes of breast cancer
Gene expression profiling has enabled molecular classification of breast cancer 
into intrinsic subtypes [10] that include:
1. Luminal A: hormone receptor positive (ER/PR +ve) and HER2 negative. They 
express low levels of the protein Ki-67, a cellular marker for proliferation. 
These cancers tend to be low grade, slow growing, good prognosis cancers.
2. Luminal B: hormone receptor positive (ER/PR +ve) and either HER2 positive 
or negative with a high level of Ki-67 expression. Faster growing and worse 
prognosis than luminal A cancers.
3. Triple negative breast cancer (TNBC)/basal-like: these are hormone receptor 
negative and HER2 negative (ER/PR/HER2 −ve). This accounts for 10–20% of 
all breast cancers, more commonly found in women with a BRCA1 PV, young 
women and African-American women. It is a rapidly growing, poor prognosis 
cancer.
4. HER2-enriched: these are HER2 positive and ER/PR negative cancer (HER2 
+ve, ER/PR −ve). They tend to grow faster than luminal cancers but can be 
treated with targeted therapies.
8. Treatments for breast cancer
The management of breast cancer is a multi-modal delivered in a multi- 
disciplinary setting. In brief, treatments include:
8.1 Surgery
Excision of the breast lesion and assessment of the axillary lymph node for 
regional metastasis. Historically this involved mastectomy with axillary clearance, 
which has now been refined following some seminal trial in breast cancer surgery 
to offering appropriate women breast conserving surgery (“lumpectomy”) and 
sentinel node biopsy. There are still important indications for mastectomy that 
would include genetic mutation status, family history, previously treated breast 
cancer, inflammatory breast cancer and patient choice.
8.2 Anti endocrine therapy
Hormone sensitive breast cancers are treated with anti hormonal therapy for 
a minimum period of 5 years that can be extended to 10–15 years based on recent 
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emerging data. There is an improved overall survival, reduced recurrence rate and 
reduction in the incidence of a contralateral breast cancer.
8.3 Radiotherapy
This is a localised, targeted therapy of high-energy X-rays that complements 
breast conservation surgery in almost all cases of invasive cancer, reducing local 
recurrence rates by almost 20–30% [11]. It may be offered following mastectomy if 
there is a high burden of disease.
8.4 Chemotherapy
This systemic treatment may be offered pre surgery (neo adjuvant) or post 
surgery (adjuvant). The choice of chemotherapy regimen is determined by number 
factors and may include anthracycline-taxane combinations. Perceived benefits 
include an improvement in survival, reduction in local recurrence and downstaging 
of tumour burden.
8.5 Anti HER2 treatment
HER2 targeted immunotherapy consists of monoclonal antibodies (e.g., 
Trastuzumab)—previously discussed.
8.6 Other treatments
PARP inhibitors: poly ADP Ribose Polymerase inhibitors are targeted therapies 
with increasing use in patients with a PV in the BRCA1/2 gene. This is discussed in 
more detail later.
Immunotherapy: this involves stimulating the host immune system actively 
immunisation (use of cancer vaccine) or passive immunisation (use of tumour 
specific antibodies or immune modulators). Of particular growing importance is 
the identification of patients with TNBC overexpressing immune evasion molecules 
(e.g., PDL: programmed death ligand) that may offer an additional treatment 
modality in this poor prognosis group [12].
9. Breast cancer genetics
The majority of breast cancers arise spontaneously—with known risk factors that 
include oestrogen exposure, reproductive history (late first or no pregnancy) and 
lifestyle practices. However, a significant proportion (20–30%) of cancers will have 
an inherited component, with family history remaining the strongest risk factor [13]. 
These tend to be classed as germline PVs in contrast to somatic  mutations—arising 
from the interactions between environment and genetics.
Approximately 5–10% of breast cancer will have a strong inherited component 
that can be further sub-divided [13] according to strength of penetrance:
















9.3 Low penetrance genes
The advent of Genome wide association studies has rapidly enabled the identi-
fication of over 100 breast cancer single nucleotide polymorphisms [14] that confer 
a small individual increase or decrease in breast cancer risk, but appear to work in a 
polygenic, multiplicative pattern contributing to a more significant risk.
10. Breast cancer and the BRCA1 gene
This tumour suppressor gene was first identified in 1990 and cloned 4 years later in 
the US [15]. During the next two decades a bitter commercial battle ensued regarding 
patenting of the genomic DNA sequence to both BRCA1 and BRCA2. Ultimately, the 
2013 US Supreme Court (Association of Molecular Pathology vs. Myriad Genetics) 
ruled that “isolation of genes found in nature do not render them patentable” [16].
The human BRCA1 gene (Chromosome 17—codes for the breast cancer type 1 
susceptibility protein) is involved in non error prone homologous DNA repair. The 
majority of PVs are frameshift resulting in a truncated protein with founder PVs in 
the Ashkenazi Jewish populations and Eastern European population [13].
10.1 Penetrance and lifetime risk
The inheritance pattern is autosomal dominant with birth incidence of a BRCA1 
PV estimated at 1 in 500–900, accounting for 7–10% of familial breast cancer [13].
Harbouring a BRCA1 PV confers a lifetime risk of breast cancer of approxi-
mately 60–85% [17, 18] and up to 60% for developing ovarian cancer (usually 
high-grade serous carcinomas). Risk of breast cancer is inversely proportional to 
age—a trend not so clearly seen in ovarian cancer (i.e., not age dependant). A recent 
prospective cohort study of 6036 BRCA1 PV carriers [19] identified that the breast 
cancer incidences per decade of age increased from 21–30 years to 31–40 years 
but then remained at 23.5–28.3 per 1000 person years from age 31 to 70 years. 
Therefore, there is a rapid increase in breast cancer incidence in early childhood 
that plateaus and remains constant throughout the remaining adult life.
Family history of breast cancers amongst first and second-degree relatives 
increased the relative risk breast cancer, a trend not seen in ovarian cancer risk in 
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families with ovarian cancer. BRCA1 PVs located outside the region bounded by 
c.2282 to c.4071 were associated with the highest risk of developing breast cancer [19].
There is a significant risk of developing a contralateral breast cancer once 
diagnosed with breast cancer. Our own studies have confirmed that this risk is 
approximately 2–3% per year, persists for at least 30 years.
Other cancers associated with this PV include pancreatic cancer (RR 2.26), uter-
ine body and cervical cancer (RR 2.65, RR 3.72, respectively) and prostate cancer in 
the under 65s (1.82) [13].
10.2 Pathology of BRCA1 cancers
BRCA1 related breast cancers are heterogenous but have some important clinical 
features. They are most often triple negative approximately 70–80% (ER, PR, Her2 
−ve) with expression of basal markers (CK5/6, CK14, SMA, P Cadherin, EGFR0). 
Histologically, they are similar to high-grade medullary carcinomas with pushing 
margins, high mitotic counts and lymphocytic infiltrate [20].
The international collaborative study (CIMBA) assessed pathological characteristics 
amongst 3797 BRCA1 carriers [21] and identified that the mean age of breast cancer 
was 40 years. The majority of breast cancers were of the ductal, no-special type variety 
with the majority of cancers demonstrating a basal-triple negative phenotype (78% 
of tumours were ER-negative, 79% were PR-negative, 90% HER2-negative and 68% 
TNBC). High-grade tumours were most common, with a clear relationship between age 
at diagnosis and grade of breast cancer—grade decreased with increasing age.
11. Breast cancer and the BRCA2 gene
This DNA repair gene was localised in the UK in 1994 and identified (cloned) 
in 1995 [22]. It is situated on Chromosome 13 at position 12.3 (13q12.3). Although 
the structures of the BRCA1 and BRCA2 gene vary from each other, there is some 
functional overlap. BRCA1 associates with BRCA2 through PALB2, a major binding 
partner of BRCA2. There is some data to suggest that BRCA1 acts as an upstream 
regulator of BRCA2 as BRCA1 promotes the concentration of PALB2 and BRCA2 at 
DNA damage sites [23].
11.1 Penetrance and lifetime risk
PVs in BRCA2 are nearly all inherited suggesting a large founder effect. This is 
important for practical purposes as certain populations can be tested for known PVs 
(e.g., single PV 999del5 accounts for almost all inherited breast and ovarian cancer 
in Iceland) [13].
Lifetime breast cancer risk has a wider range (40–85%) compared with 
BRCA1, and a slightly lower risk of developing ovarian cancer (20–30%) [13]. 
Approximately 1 in 400–800 women carry a PV (outbred population) that accounts 
for 10% of familial breast/ovarian cancer [14].
Several other cancers are more commonly associated with these PV: cholangio-
carcinoma, melanoma, pancreatic cancer (overall RR 4.1), gastric cancer (RR 2.7) 
and prostate cancer (10–20% life time risk) [13]. Approximately 10% of male breast 
cancer is associated with BRCA2, a trend not seen in BRCA1 PVs.
11.2 Pathology of BRCA2 cancers
Breast cancer in BRCA2 PVs carriers is a more heterogeneous group compared 
with BRCA1 carriers, with more semblance to sporadic breast cancers. Pathology 
7
Breast Cancer and BRCA1 and BRCA2 Pathogenic Variants
DOI: http://dx.doi.org/10.5772/intechopen.90926
shows that these breast cancers are more often ER+ve compared with controls, with 
some studies showing increased DCIS and lobular cancer [20].
A study of breast cancer amongst 6893 BRCA1 and BRCA2 PV carriers found 
similar proportion of ductal, no-special type cancers (approximately 80%) with a 
four-fold increase in lobular cancers amongst BRCA2 carriers (8% compared with 
2% in BRCA1 patients) [21]. Overall, there were double the number of Grade 1 and 
2 cancers in the BRCA2 compared with BRCA1, with more Grade 3 cancers in the 
BRCA1 group (77% compared with 50% in BRCA2 carriers).
There is paucity of data regarding the pre-invasive progression pathway amongst 
BRCA1/2 carriers. Whereas a DCIS associated pre-malignant pathway has been 
postulated in sporadic cancers, this has not been shown in BRCA1/2 PV carriers. 
There is conflicting data regarding incidence of DCIS in this patient group. Some 
reports suggest an increased incidence of DCIS identified in risk-reducing mastec-
tomy specimens as opposed to other studies identifying DCIS less frequently near 
the invasive cancer compared with sporadic tumours [24].
12. Prognosis for BRCA mutated breast cancer
The POSH study (Prospective Outcomes in Sporadic versus Hereditary breast 
cancer), designed as a prospective cohort study, assessed the outcomes of women 
aged 40 years or below diagnosed with an invasive breast cancer in the UK [25]. 
With a follow up of nearly 10 years, 12% of all patients were identified with a PV 
in either the BRCA1/2 gene. Multivariate analysis identified no overall difference in 
survival between BRCA positive or BRCA negative patients. Amongst patients with 
TNBC, there was a short-term survival benefit at 2 years amongst BRCA carriers. 
The authors hypothesised that this short-lived benefit may reflect greater sensitivity 
of BRCA mutant cancer to chemotherapy and/or greater visibility of BRCA related 
cancers to the immune system [25].
Studies prior to the POSH studied inconsistent effects of BRCA1/2 PV status on 
breast cancer outcomes. A meta-analysis of 66 relevant studies [26] did not identify 
inferior breast cancer outcomes amongst BRCA1/2 PV carriers despite the biological 
differences in breast cancer type already discussed.
In addition these women have similar survival whether they are treated with breast 
conservation surgery or a mastectomy, despite having significant higher rates of local 
failure with breast conservation [27]. An international longitudinal study of 655 
patients with BRCA1/2 PVs showed no differences in overall survival, distant or regional 
recurrence at 20 years whether women underwent a mastectomy or breast conservation 
therapy with radiotherapy. Interestingly, most local recurrences are second primary 
breast cancers rather than failure to control the primary breast cancer [27].
12.1 Radiotherapy
The effect of radiotherapy on BRCA1/2 associated breast cancer merits consid-
eration. These cancers are characterised by defects in homologous recombination, 
resulting in inadequate repair of double stranded DNA breaks—a hallmark of PVs 
in the BRCA1/2 genes. In particular, younger patients with a higher rate of cell 
proliferation may be more susceptible to the carcinogenic effects of radiotherapy. 
Studies have confirmed an increased risk of contralateral breast cancer amongst 
young patients with a sporadic breast cancer treated with radiotherapy suggesting 
an effect of low-dose scatter radiation to surround healthy tissue [28].
In patients with a BRCA1/2 PV associated breast cancer treated with unilateral 
radiotherapy, hypothetically there should be an increased risk of contralateral 
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breast cancers particularly in the younger patient group, as the contralateral healthy 
breast will receive some scatter radiation. In addition, adjuvant radiotherapy to the 
index breast of BRCA1/2 PV carriers should be more efficacious compared with 
sporadic cancer by virtue of the aberration in DNA repair. A recent Dutch study 
was not able to demonstrate any association between radiotherapy and contralateral 
breast cancer risk [29]. They observed a growing trend in their population group 
of BRCA1/2 PV carriers away from breast conservation with radiotherapy towards 
mastectomy and contralateral mastectomy.
12.2 Chemotherapy
Healthy, normal breast tissue exposed to toxic, chemotherapeutic agents will 
result in DNA damage that is then partly repaired by the BRCA1/2 DNA damage 
response. Different chemotherapy agents used to treat breast cancers exhibit differ-
ences in mechanism of action. Taxane-based agents work by disrupting the micro-
tubule function whereas anthracyclines induce topoisomerase II mediated toxicity, 
DNA intercalation and generation of reactive oxidative species. In vitro studies have 
shown that platinum based chemotoxic agents have a greater sensitivity for BRCA1 
mutated cell lines which may in part be due to the disruption of DNA [30].
12.3 PARP inhibitors
This class of targeted therapy work on the principle of “synthetic lethality” [31], 
whereby a defect in one gene/protein results in cell survival however when synthe-
sised with another gene/protein results in cell death.
Poly ADP Ribose Polymerase (PARP1) is an important protein that repairs single 
strand DNA breaks. Drugs that inhibit this protein (PARP inhibitors) result in 
multiple breaks in double stranded DNA that cannot be repaired, resulting in cell 
death. A proof of concept international study [32] showed a favourable therapeutic 
index for Olaparib (an orally active PARP inhibitor) amongst patients with advanced 
or recurrent breast cancer who harboured a BRCA1/2 PV. The OlympiAD study, an 
international, randomised, Phase III trial recently reported an improved progression 
free survival amongst patients with metastatic breast cancer who were HER2 negative 
with a germline PV in either BRCA1/2 [33]. Future directions of research will include 
combining PARP inhibitors with radiotherapy and platinum based agents [34].
12.4 Risk-reducing surgery
Bilateral risk-reducing mastectomy (BRRM) offers the greatest magnitude of 
overall risk reduction in health patients harboring a BRCA1/2 PV by removing in 
excess of 90% of the breast tissue. A recent Cochrane review showed that BRRM 
reduces the risk of developing breast cancer by 85–100 [35] in high-risk patients. It 
also showed that BRRM reduced the risk of dying from breast cancer by 81–100% in 
high-risk patients and 100% in the moderate risk group.
Uptake of BRRM varies amongst women in this high-risk group. From a patient’s 
perspective, young age and motherhood seem to be positive predictors for choosing 
surgery [36–38]. Several studies have shown international variations in uptake of 
BRRM with the highest rates in the UK and the Netherlands (33–50%) and the US 
(36%) compared with Poland (3%) and Israel (4%) [39, 40]. Differences in culture, 
healthcare systems and access to genetic testing are likely to contribute to these 
differences. However, wide variations are found within countries—for example in 
three different Canadian regions, the range of uptake was from 8 to 46% [41]— 
suggesting that other factors are important.
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Media coverage and public interest in BRRM has been heightened since 2013 
when Angelina Jolie’s revealed her personal experience of bilateral mastectomies 
based on her inheriting a pathogenic BRCA1 PV from her late mother. The so-called 
“Angelina Jolie Effect” ensued with increased uptake of genetic testing and BRRM 
in the US and UK [42–44].
12.5 Bilateral risk-reducing salpingo oophorectomy (BRRSO)
Women choosing this procedure will reduce their risk of developing ovarian by 
almost 90%. In addition, there appears to be a reduction in their subsequent risk of 
developing breast cancer (premenopausal women) [45, 46], with several previous 
studies showing a risk-reduction of almost 50%. Unlike breast cancer, surveillance 
for ovarian cancer is limited to measurements of tumour markers (CA125) and 
transvaginal ultra-sound—both of which may lack sensitivity. As such, uptake of 
BRRSO is high (up to 75%).
BRRSO renders women post menopausal (surgical menopause) with additional 
risks to the cardiovascular and skeletal system. In addition, most women are recom-
mended to have completed their family prior to considering this surgery. The cli-
macteric symptoms following this procedure can be debilitating and many women 
will consider use of HRT to combat these symptoms. Use of HRT itself may increase 
the risk of developing breast cancer in these women already deemed at high-risk.
The risk reduction for breast cancer has recently been reassessed for potential 
selection bias [47]. This study used the same methodology previously described 
[45] to study a cohort of Dutch BRCA1/2 healthy carriers and found that following 
BRRSO, the incidence of breast cancer was almost halved (Hazard Ratio 0.36–0.62). 
A revised analysis taking into account the various biases described above showed no 
real protective effect of BRRSO on breast cancer development (Hazard Ratio 1.09). 
This has important clinical implications when considering the variations of uptake 
of BRRM compared with BRRSO—women only choosing BRRSO over BRRM may 
have had their breast cancer risk reduction overestimated if they only chose BRRSO.
12.6 Chemoprevention
In the UK, healthy women with a BRCA1/2 PV may consider three medications 
to reduce their risk:
Tamoxifen: this selective oestrogen receptor modulator (first generation) has 
been shown to reduce the risk in asymptomatic women by approximately 40–50% 
[48]. In women with breast cancer, tamoxifen has a similar risk reduction in devel-
oping CBC. The side-effect profile (hot flushes, increased incidence of endometrial 
cancer, thromboembolic phenomenon) is an important consideration as less than 
15% of women will choose this and remain compliant [49]. Tamoxifen may be 
considered in pre and post menopausal women.
Raloxifene (second generation SERM), used in the prevention and treatment of 
osteoporosis has a much better side effect profile with no increase in endometrial 
cancers but increases thromboembolic risk similar to tamoxifen. Risk reduction was 
inferior to tamoxifen over an extended follow [50]. Raloxifene is considered in the 
post-menopausal setting only.
Aromatase inhibitor: Exemestane has been shown to offer 65% relative risk 
reduction in post-menopausal women at increased risk with a minimal side-effect 
profile [51]. The IBIS II trial (International Breast Cancer Intervention Studies) 
randomised post-menopausal women with an increased risk of breast cancer to 
anastrozole or placebo. At 5 years follow-up, 2% of women taking Anastrozole had 
developed breast cancer compared with 4% in the placebo group [52].
Breast Cancer and Breast Reconstruction
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Although there is not good quality evidence to show that endocrine therapy is 
not effective in BRCA1 as 70–80% of breast cancers are triple negative and these 
medications only reduce ER positive cancers they may have less efficacy in BRCA1 
PV carriers.
12.7 Lifestyle
Worldwide, the number of oestrogen receptor positive breast cancers is increas-
ing with a reverse pattern seen with oestrogen negative cancer. In developed 
countries, hormone sensitive breast cancer is particularly amenable to lifestyle 
prevention—with recent studies suggesting that modification of lifestyle measure 
may prevent up to 30% of breast cancers [53].
Amongst BRCA carriers, smoking, increased weight and reduced physical 
activity further increases the risk of breast cancer. These lifestyle measures need to 
commence in adolescence and adherence to this (150 min weekly activity, BMI < 25, 
<1 alcoholic drink daily) has been shown to reduce mortality in BRCA carriers by 
almost 60% [54].
The LIBRE study (Lifestyle Intervention in BRCA1/2 PV carriers) aims to ran-
domise healthy BRCA1/2 PV carriers to a number of lifestyles interventions versus a 
control group and assess changes in physical and psychological well being [55].
13. Discussion
The worldwide burden of breast cancer poses significant challenges to health 
care providers. There is an increasing awareness that this heterogenous disease 
requires a multi-modality approach with consideration to both prevention and 
treatment.
Diet and lifestyle are important modifiers in the prevention of breast cancer. 
Adherence to physical activity and alcohol guidelines may reduce the risk of devel-
oping breast cancer (pre and post menopausal), with weight control being more 
important in prevention in the post menopausal cohort [56]. Energy restriction, in 
particular intermittently is association with changes in breast gene expression and 
systemic metabolism [57]. Future studies will need to assess the mechanism and 
clinical significance in breast cancer pathogenesis.
Breast cancer metabolomics is an area of growing interest. A recent study was 
able to determine a differential metabolic signature based on BRCA1 functionality 
[58] and may provide future biomarkers.
An area of interest is establishing whether breast cancer may be considered a 
communicable disease. There is established causality of infection with the Human 
Papilloma Virus and a number of cancers namely cervical cancer and associations 
with penile, anal and vulvar cancer. A similar aetiology has been postulated with 
breast cancer with entry of the virus via the nipple areolar complex resulting in 
biological activity within the mammary duct epithelium resulting in breast cancer. 
Data from Norway [59] have identified a possible association of pre-malignant 
changes in the cervix and an increased risk of subsequent breast cancer. A subse-
quent UK study [60] has identified the presence of high-risk HPV DNA in 42% of 
breast cancers with viral activity confirmed in less than 20% of invasive cancers 
suggesting that this may be an area of on going interest in the future.
Gene therapy in cancer aims at correcting specific genetic anomalies contribut-
ing to the development of certain cancers. This can be subdivided into germline and 
somatic cell gene therapy and is an important treatment modality in disease pro-
cesses like cystic fibrosis and blood disorders. Several BRCA1 retroviral vectors were 
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assessed in Phase 2 clinical trials in ovarian cancer almost two decades ago [61] with 
some initial potential as a therapeutic modality. The lack of progress in viral vectors 
suggests that newer techniques such as gene editing may find a place.
The UK 100,000 Genome project completed recruitment in 2018. Breast cancer 
patients represent a significant proportion of the 85,000 patients either with a can-
cer or rare disease diagnosis. Whole genome sequencing has allowed rapid analysis 
of the entire genome in this patient subgroup and is already aiding clinicians in 
making therapeutic decision in breast cancer, although no new hereditary genes 
have yet been identified from this initiative.
14. Conclusion
Pathogenic variants in the BRCA1 and BRCA2 gene confer a substantial lifetime 
risk of developing breast cancer. These breast cancers display characteristic clini-
cal and pathological features that are important in the clinical management of the 
disease.
Multiple strategies exist for healthy individuals harbouring PVs in these genes. 
This comprises surveillance using modern day radiology (mammography and 
MRI scans) and risk reducing strategies. The latter include bilateral risk-reducing 
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